Print Departments and specialties Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery. Departments with related expertise Cancer Care at Mayo Clinic Oncology (Medical) Urology Areas that research this procedure Urology Research ResearchDoctors and scientists in urology research at Mayo Clinic are studying new treatment options for prostate cancer and other urologic conditions. Researchers are actively involved in studying long-term outcomes after radical prostatectomy. For decades, Mayo Clinic has been compiling a database from records of men who have had surgery for prostate cancer. Mayo researchers use this information to monitor outcomes, search for trends and ensure overall quality of care. Prostate cancer research is conducted in coordination with the Mayo Clinic Comprehensive Cancer Center. The Mayo Clinic Comprehensive Cancer Center receives funding from the National Cancer Institute and is designated as a comprehensive cancer center — recognition for an institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment. The Department of Urology at Mayo Clinic is engaged in continuous research to advance new treatment options for prostate cancer and other urologic conditions. Recent studies include evaluating quality of life and operative outcomes after robot-assisted prostatectomy. This type of research allows Mayo Clinic surgeons to provide the highest level of care for people who have this procedure. Additional research is being done on the biology of prostate cancer. PublicationsSee a list of publications by Mayo Clinic authors on prostatectomy on PubMed, a service of the National Library of Medicine. By Mayo Clinic Staff Prostatectomy care at Mayo Clinic Request an appointment AboutCare at Mayo Clinic Nov. 24, 2022 Print Show references AskMayoExpert. Radical prostatectomy (adult). Mayo Clinic; 2019. Cunningham GR, et al. Surgical treatment of benign prostatic hyperplasia. https://www.uptodate.com/contents/search. Accessed March 31, 2020. Office of Patient Education. Your robotic-assisted prostate surgery. Mayo Clinic; 2018. Surgery for prostate cancer. Prostate cancer foundation. https://www.pcf.org/about-prostate-cancer/prostate-cancer-treatment/surgery-prostate-cancer/. Accessed March 27, 2020. Partin AW, et al., eds. Simple prostatectomy: Open and robotic-assisted laparoscopic approaches. In: Campbell-Walsh-Wein Urology. 12th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed April 1, 2020. Ilic D, et al. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database of Systematic Reviews. 2017; doi:10.1002/14651858.CD009625.pub2. Moreira DM, et al. Evaluation of pT0 prostate cancer in patients undergoing radical prostatectomy. BJU International. 2017; doi:10.1111/bju.13266. Motterle G, et al. The role of radical prostatectomy and lymph node dissection in clinically node positive patients. Frontiers in Oncology. 2019; doi:10.3389/fonc.2019.01395. Warner KJ. Allscripts EPSi. Mayo Clinic. Feb. 24, 2020. Costello AJ. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nature Reviews|Urology. 2020; doi:10.1038/s41585-020-0287-y. Agarwal DK, et al. Initial experience with da Vinci single-port robot-assisted radical prostatectomies. European Urology. 2020; doi:10.1016/j.eururo.2019.04.001. Ashfaq A, et al. Incidence and outcomes of ventral hernia repair after robotic retropubic prostatectomy: A retrospective cohort of 570 consecutive cases. International Journal of Surgery. 2017; doi:10.1016/j.ijsu.2016.12.034. Moris L, et al. Impact of lymph node burden on survival of high-risk prostate cancer patients following radical prostatectomy and pelvic lymph node dissection. Frontiers in Surgery. 2016; doi:10.3389/fsurg.2016.00065. Kaushik D, et al. Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer. International Brazilian Journal of Urology. 2016; doi:10.1590/S1677-5538.IBJU.2016.0290. Alshalalfa M, et al. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients. Oncotarget. 2017; doi:10.18632/oncotarget.15133. Related Prostate cancer Products & Services A Book: Mayo Clinic Family Health Book Newsletter: Mayo Clinic Health Letter — Digital Edition Show more products and services from Mayo Clinic ProstatectomyAboutDoctors&DepartmentsCare atMayoClinic PRC-20309673 Patient Care & Health Information Tests & Procedures Prostatectomy